Author

P. Lu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Targeting metabolic cell death in cancer to reverse drug resistance.

Evasion of apoptosis is a typical feature of malignant tumors developing to survive therapeutic stress. As a result, chemotherapeutic drugs that primarily induce apoptosis can no longer effectively kill tumor cells, which brings challenges to clinical cancer treatment. Recent evidence indicates that targeting key nodes...

Ting-Ting Liu, Yi-Wu Dang, Wen Zhang et al. · Biochimica et biophysica act... · 0 citations

Oct 2026

Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial.

The addition of camrelizumab to neoadjuvant docetaxel plus carboplatin significantly increased the pCR rate in patients with stage II-III TNBC, with a manageable safety profile.

D. Jiao, X. Sun, J. Qiao et al. · Annals of Oncology · 0 citations